Alternaturals, Inc.
ANAS · OTC
3/31/2025 | 12/31/2024 | 9/30/2024 | 6/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.00 | 0.00 | 0.00 |
| FCF Yield | 0.00% | 0.00% | 0.00% | 0.00% |
| EV / EBITDA | -157.84 | 0.00 | -82.78 | -148.72 |
| Quality | ||||
| ROIC | -9.03% | 0.00% | -13.45% | -7.06% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.00 | 1.00 | 4.58 | – |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 0.00% | 0.00% | 0.00% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | -8.42 | 0.00 | -4.98 | -7.59 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |